Luminex Competitors

Thermo Fisher Scientific (NYSE:TMO) and Luminex (NASDAQ:LMNX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings and risk.

Institutional and Insider Ownership

87.2% of Thermo Fisher Scientific shares are owned by institutional investors. Comparatively, 88.1% of Luminex shares are owned by institutional investors. 0.4% of Thermo Fisher Scientific shares are owned by company insiders. Comparatively, 9.4% of Luminex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Thermo Fisher Scientific and Luminex's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Thermo Fisher Scientific and Luminex's revenue, earnings per share and valuation.

Thermo Fisher Scientific has higher revenue and earnings than Luminex. Luminex is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Thermo Fisher Scientific and Luminex, as provided by MarketBeat.com.

Thermo Fisher Scientific currently has a consensus target price of $526.3684, suggesting a potential upside of 9.92%. Luminex has a consensus target price of $38.00, suggesting a potential upside of 15.33%. Given Luminex's stronger consensus rating and higher probable upside, analysts clearly believe Luminex is more favorable than Thermo Fisher Scientific.

Volatility & Risk

Thermo Fisher Scientific has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Luminex has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.

Dividends

Thermo Fisher Scientific pays an annual dividend of $1.04 per share and has a dividend yield of 0.2%. Luminex pays an annual dividend of $0.40 per share and has a dividend yield of 1.2%. Thermo Fisher Scientific pays out 8.4% of its earnings in the form of a dividend. Luminex pays out -190.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Thermo Fisher Scientific has raised its dividend for 3 consecutive years and Luminex has raised its dividend for 1 consecutive years. Luminex is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Thermo Fisher Scientific beats Luminex on 10 of the 17 factors compared between the two stocks.

Luminex (NASDAQ:LMNX) and Illumina (NASDAQ:ILMN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation.

Profitability

This table compares Luminex and Illumina's net margins, return on equity and return on assets.

Volatility and Risk

Luminex has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Luminex and Illumina, as reported by MarketBeat.

Luminex currently has a consensus target price of $38.00, indicating a potential upside of 15.33%. Illumina has a consensus target price of $370.5789, indicating a potential downside of 8.13%. Given Luminex's stronger consensus rating and higher possible upside, equities research analysts plainly believe Luminex is more favorable than Illumina.

Insider & Institutional Ownership

88.1% of Luminex shares are owned by institutional investors. Comparatively, 90.0% of Illumina shares are owned by institutional investors. 9.4% of Luminex shares are owned by company insiders. Comparatively, 0.4% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Luminex and Illumina's revenue, earnings per share and valuation.

Illumina has higher revenue and earnings than Luminex. Luminex is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Summary

Illumina beats Luminex on 11 of the 14 factors compared between the two stocks.

Luminex (NASDAQ:LMNX) and Agilent Technologies (NYSE:A) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Luminex and Agilent Technologies, as provided by MarketBeat.com.

Luminex currently has a consensus price target of $38.00, indicating a potential upside of 15.33%. Agilent Technologies has a consensus price target of $104.70, indicating a potential downside of 20.63%. Given Luminex's stronger consensus rating and higher possible upside, equities analysts plainly believe Luminex is more favorable than Agilent Technologies.

Institutional & Insider Ownership

88.1% of Luminex shares are held by institutional investors. 9.4% of Luminex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Dividends

Luminex pays an annual dividend of $0.40 per share and has a dividend yield of 1.2%. Agilent Technologies pays an annual dividend of $0.78 per share and has a dividend yield of 0.6%. Luminex pays out -190.5% of its earnings in the form of a dividend. Agilent Technologies pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Luminex has increased its dividend for 1 consecutive years and Agilent Technologies has increased its dividend for 1 consecutive years. Luminex is clearly the better dividend stock, given its higher yield and lower payout ratio.

Profitability

This table compares Luminex and Agilent Technologies' net margins, return on equity and return on assets.

Risk and Volatility

Luminex has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.

Earnings and Valuation

This table compares Luminex and Agilent Technologies' gross revenue, earnings per share (EPS) and valuation.

Agilent Technologies has higher revenue and earnings than Luminex. Luminex is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Agilent Technologies beats Luminex on 9 of the 16 factors compared between the two stocks.

Mettler-Toledo International (NYSE:MTD) and Luminex (NASDAQ:LMNX) are both computer and technology companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Insider and Institutional Ownership

93.2% of Mettler-Toledo International shares are held by institutional investors. Comparatively, 88.1% of Luminex shares are held by institutional investors. 3.2% of Mettler-Toledo International shares are held by insiders. Comparatively, 9.4% of Luminex shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Mettler-Toledo International and Luminex, as provided by MarketBeat.com.

Mettler-Toledo International presently has a consensus target price of $971.3750, suggesting a potential downside of 20.54%. Luminex has a consensus target price of $38.00, suggesting a potential upside of 15.33%. Given Luminex's stronger consensus rating and higher probable upside, analysts clearly believe Luminex is more favorable than Mettler-Toledo International.

Profitability

This table compares Mettler-Toledo International and Luminex's net margins, return on equity and return on assets.

Volatility and Risk

Mettler-Toledo International has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Luminex has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

Valuation & Earnings

This table compares Mettler-Toledo International and Luminex's gross revenue, earnings per share (EPS) and valuation.

Mettler-Toledo International has higher revenue and earnings than Luminex. Luminex is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Summary

Mettler-Toledo International beats Luminex on 9 of the 13 factors compared between the two stocks.

Luminex (NASDAQ:LMNX) and Waters (NYSE:WAT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership.

Profitability

This table compares Luminex and Waters' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Luminex and Waters, as reported by MarketBeat.

Luminex presently has a consensus price target of $38.00, suggesting a potential upside of 15.33%. Waters has a consensus price target of $224.20, suggesting a potential downside of 27.00%. Given Luminex's stronger consensus rating and higher possible upside, analysts plainly believe Luminex is more favorable than Waters.

Insider and Institutional Ownership

88.1% of Luminex shares are owned by institutional investors. Comparatively, 91.8% of Waters shares are owned by institutional investors. 9.4% of Luminex shares are owned by company insiders. Comparatively, 1.5% of Waters shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Luminex and Waters' revenue, earnings per share (EPS) and valuation.

Waters has higher revenue and earnings than Luminex. Luminex is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Luminex has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Waters has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.

Summary

Waters beats Luminex on 8 of the 13 factors compared between the two stocks.

Bio-Rad Laboratories (NYSE:BIO) and Luminex (NASDAQ:LMNX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.

Profitability

This table compares Bio-Rad Laboratories and Luminex's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current recommendations and price targets for Bio-Rad Laboratories and Luminex, as provided by MarketBeat.com.

Bio-Rad Laboratories presently has a consensus price target of $700.00, indicating a potential upside of 16.17%. Luminex has a consensus price target of $38.00, indicating a potential upside of 15.33%. Given Bio-Rad Laboratories' higher probable upside, research analysts plainly believe Bio-Rad Laboratories is more favorable than Luminex.

Institutional & Insider Ownership

63.0% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 88.1% of Luminex shares are held by institutional investors. 27.5% of Bio-Rad Laboratories shares are held by company insiders. Comparatively, 9.4% of Luminex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Bio-Rad Laboratories has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Luminex has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

Earnings and Valuation

This table compares Bio-Rad Laboratories and Luminex's gross revenue, earnings per share (EPS) and valuation.

Bio-Rad Laboratories has higher revenue and earnings than Luminex. Luminex is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

Bio-Rad Laboratories beats Luminex on 11 of the 13 factors compared between the two stocks.